Solventum Corporation (NYSE: SOLV) Stock Competitors & Peer Comparison
See SOLV's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SOLV and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SOLV | $88.59 | +2.46% | 15.3B | 12.48 | $7.10 | N/A |
| ISRG | $394.51 | -1.68% | 139.4B | 41.01 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.04% |
| BDX | $183.40 | +0.79% | 50.5B | 14.11 | $13.00 | +2.04% |
| MDLN | $35.74 | +0.45% | 30.2B | 26.19 | $1.36 | N/A |
| WST | $349.42 | +0.94% | 24.6B | 43.83 | $7.97 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $76.17 | -0.56% | 14.9B | 16.70 | $4.56 | N/A |
| BAX | $26.73 | -1.18% | 13.8B | 12.85 | $2.08 | +0.75% |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.04% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
SOLV vs ISRG Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ISRG has a market cap of 139.4B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ISRG trades at $394.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ISRG's P/E ratio is 41.01. In terms of profitability, SOLV's ROE is +0.29%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, SOLV is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
SOLV vs BDXA Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas BDXA's P/E ratio is 45.70. In terms of profitability, SOLV's ROE is +0.29%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
SOLV vs BDX Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, BDX has a market cap of 50.5B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while BDX trades at $183.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas BDX's P/E ratio is 14.11. In terms of profitability, SOLV's ROE is +0.29%, compared to BDX's ROE of +0.04%. Regarding short-term risk, SOLV is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
SOLV vs MDLN Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, MDLN has a market cap of 30.2B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while MDLN trades at $35.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas MDLN's P/E ratio is 26.19. In terms of profitability, SOLV's ROE is +0.29%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, SOLV is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
SOLV vs WST Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, WST has a market cap of 24.6B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while WST trades at $349.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas WST's P/E ratio is 43.83. In terms of profitability, SOLV's ROE is +0.29%, compared to WST's ROE of +0.19%. Regarding short-term risk, SOLV is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
SOLV vs HOLX Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas HOLX's P/E ratio is 31.54. In terms of profitability, SOLV's ROE is +0.29%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, SOLV is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
SOLV vs COO Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, COO has a market cap of 14.9B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while COO trades at $76.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas COO's P/E ratio is 16.70. In terms of profitability, SOLV's ROE is +0.29%, compared to COO's ROE of +0.03%. Regarding short-term risk, SOLV is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check COO's competition here
Baxter International Inc. (NYSE: BAX)
SOLV vs BAX Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, BAX has a market cap of 13.8B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while BAX trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas BAX's P/E ratio is 12.85. In terms of profitability, SOLV's ROE is +0.29%, compared to BAX's ROE of -0.17%. Regarding short-term risk, SOLV is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check BAX's competition here
Becton, Dickinson and Company (NYSE: BDXB)
SOLV vs BDXB Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas BDXB's P/E ratio is 7.60. In terms of profitability, SOLV's ROE is +0.29%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, SOLV is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check BDXB's competition here
Repligen Corporation (NASDAQ: RGEN)
SOLV vs RGEN Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, RGEN has a market cap of 9.4B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while RGEN trades at $166.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas RGEN's P/E ratio is 92.68. In terms of profitability, SOLV's ROE is +0.29%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, SOLV is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
SOLV vs AVTR Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, AVTR has a market cap of 9.2B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while AVTR trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas AVTR's P/E ratio is 16.07. In terms of profitability, SOLV's ROE is +0.29%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, SOLV is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
SOLV vs ATR Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ATR trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ATR's P/E ratio is 23.09. In terms of profitability, SOLV's ROE is +0.29%, compared to ATR's ROE of +0.14%. Regarding short-term risk, SOLV is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
SOLV vs BLCO Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while BLCO trades at $17.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas BLCO's P/E ratio is 26.20. In terms of profitability, SOLV's ROE is +0.29%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, SOLV is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
SOLV vs TFX Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, TFX has a market cap of 6.1B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while TFX trades at $137.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas TFX's P/E ratio is 15.67. In terms of profitability, SOLV's ROE is +0.29%, compared to TFX's ROE of -0.32%. Regarding short-term risk, SOLV is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
SOLV vs STVN Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while STVN trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas STVN's P/E ratio is 32.01. In terms of profitability, SOLV's ROE is +0.29%, compared to STVN's ROE of +0.09%. Regarding short-term risk, SOLV is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
SOLV vs MMSI Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, MMSI has a market cap of 5.4B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while MMSI trades at $90.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas MMSI's P/E ratio is 23.21. In terms of profitability, SOLV's ROE is +0.29%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, SOLV is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
SOLV vs ICUI Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ICUI trades at $182.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ICUI's P/E ratio is 22.84. In terms of profitability, SOLV's ROE is +0.29%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, SOLV is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
SOLV vs NVST Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, NVST has a market cap of 4.6B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while NVST trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas NVST's P/E ratio is 19.10. In terms of profitability, SOLV's ROE is +0.29%, compared to NVST's ROE of +0.04%. Regarding short-term risk, SOLV is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
SOLV vs PLSE Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, PLSE has a market cap of 3.1B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while PLSE trades at $44.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas PLSE's P/E ratio is -37.75. In terms of profitability, SOLV's ROE is +0.29%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, SOLV is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check PLSE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
SOLV vs XRAY Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while XRAY trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas XRAY's P/E ratio is 8.10. In terms of profitability, SOLV's ROE is +0.29%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, SOLV is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check XRAY's competition here
AtriCure, Inc. (NASDAQ: ATRC)
SOLV vs ATRC Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ATRC has a market cap of 2.3B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ATRC trades at $44.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ATRC's P/E ratio is 1375.78. In terms of profitability, SOLV's ROE is +0.29%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, SOLV is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ATRC's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
SOLV vs LMAT Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while LMAT trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas LMAT's P/E ratio is 30.29. In terms of profitability, SOLV's ROE is +0.29%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, SOLV is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
SOLV vs BLFS Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while BLFS trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas BLFS's P/E ratio is -165.93. In terms of profitability, SOLV's ROE is +0.29%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, SOLV is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check BLFS's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
SOLV vs KMTS Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while KMTS trades at $28.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas KMTS's P/E ratio is -11.87. In terms of profitability, SOLV's ROE is +0.29%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, SOLV is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check KMTS's competition here
Azenta, Inc. (NASDAQ: AZTA)
SOLV vs AZTA Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while AZTA trades at $33.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas AZTA's P/E ratio is 79.48. In terms of profitability, SOLV's ROE is +0.29%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, SOLV is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check AZTA's competition here
STAAR Surgical Company (NASDAQ: STAA)
SOLV vs STAA Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while STAA trades at $26.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas STAA's P/E ratio is 45.93. In terms of profitability, SOLV's ROE is +0.29%, compared to STAA's ROE of +0.01%. Regarding short-term risk, SOLV is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
SOLV vs QDEL Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, QDEL has a market cap of 975.1M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while QDEL trades at $14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas QDEL's P/E ratio is 10.67. In terms of profitability, SOLV's ROE is +0.29%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, SOLV is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
SOLV vs ATRI Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ATRI's P/E ratio is 64.50. In terms of profitability, SOLV's ROE is +0.29%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, SOLV is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
SOLV vs ANGO Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ANGO has a market cap of 655.1M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ANGO trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ANGO's P/E ratio is -40.64. In terms of profitability, SOLV's ROE is +0.29%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, SOLV is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
SOLV vs NNNN Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, NNNN has a market cap of 381.9M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while NNNN trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas NNNN's P/E ratio is 125.72. In terms of profitability, SOLV's ROE is +0.29%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, SOLV is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
SOLV vs SMTI Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, SMTI has a market cap of 313.9M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while SMTI trades at $34.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas SMTI's P/E ratio is -569.17. In terms of profitability, SOLV's ROE is +0.29%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, SOLV is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
SOLV vs OSUR Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, OSUR has a market cap of 264.4M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while OSUR trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas OSUR's P/E ratio is -6.98. In terms of profitability, SOLV's ROE is +0.29%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
SOLV vs INFU Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, INFU has a market cap of 247M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while INFU trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas INFU's P/E ratio is 29.85. In terms of profitability, SOLV's ROE is +0.29%, compared to INFU's ROE of +0.15%. Regarding short-term risk, SOLV is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
SOLV vs UTMD Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, UTMD has a market cap of 226.1M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while UTMD trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas UTMD's P/E ratio is 21.01. In terms of profitability, SOLV's ROE is +0.29%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, SOLV is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
SOLV vs PDEX Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, PDEX has a market cap of 214M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while PDEX trades at $67.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas PDEX's P/E ratio is 23.60. In terms of profitability, SOLV's ROE is +0.29%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, SOLV is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
SOLV vs KRMD Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, KRMD has a market cap of 156.2M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while KRMD trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas KRMD's P/E ratio is -85.00. In terms of profitability, SOLV's ROE is +0.29%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, SOLV is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
SOLV vs MBOT Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, MBOT has a market cap of 70.6M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while MBOT trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas MBOT's P/E ratio is -5.96. In terms of profitability, SOLV's ROE is +0.29%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, SOLV is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
SOLV vs AKYA Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas AKYA's P/E ratio is -1.34. In terms of profitability, SOLV's ROE is +0.29%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, SOLV is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
SOLV vs DXR Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, DXR has a market cap of 60.7M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while DXR trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas DXR's P/E ratio is 27.20. In terms of profitability, SOLV's ROE is +0.29%, compared to DXR's ROE of +0.22%. Regarding short-term risk, SOLV is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
SOLV vs STSS Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas STSS's P/E ratio is -0.02. In terms of profitability, SOLV's ROE is +0.29%, compared to STSS's ROE of -1.54%. Regarding short-term risk, SOLV is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
SOLV vs OMIC Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas OMIC's P/E ratio is -0.58. In terms of profitability, SOLV's ROE is +0.29%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, SOLV is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
SOLV vs IGAP Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas IGAP's P/E ratio is -10.52. In terms of profitability, SOLV's ROE is +0.29%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, SOLV is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
SOLV vs NEPH Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, NEPH has a market cap of 50.2M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while NEPH trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas NEPH's P/E ratio is 77.08. In terms of profitability, SOLV's ROE is +0.29%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, SOLV is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
SOLV vs POCI Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, POCI has a market cap of 48M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while POCI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas POCI's P/E ratio is -6.09. In terms of profitability, SOLV's ROE is +0.29%, compared to POCI's ROE of -0.37%. Regarding short-term risk, SOLV is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
SOLV vs MLSS Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, MLSS has a market cap of 43.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while MLSS trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas MLSS's P/E ratio is -8.25. In terms of profitability, SOLV's ROE is +0.29%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, SOLV is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
SOLV vs HBIO Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, HBIO has a market cap of 30M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while HBIO trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas HBIO's P/E ratio is -18.49. In terms of profitability, SOLV's ROE is +0.29%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, SOLV is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
SOLV vs SDC Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas SDC's P/E ratio is -0.03. In terms of profitability, SOLV's ROE is +0.29%, compared to SDC's ROE of -1.96%. Regarding short-term risk, SOLV is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check SDC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
SOLV vs ZJYL Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ZJYL has a market cap of 26.5M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ZJYL trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ZJYL's P/E ratio is 21.13. In terms of profitability, SOLV's ROE is +0.29%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
SOLV vs IVC Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas IVC's P/E ratio is -0.79. In terms of profitability, SOLV's ROE is +0.29%, compared to IVC's ROE of -0.46%. Regarding short-term risk, SOLV is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
SOLV vs RVP Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, RVP has a market cap of 20.7M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas RVP's P/E ratio is -2.10. In terms of profitability, SOLV's ROE is +0.29%, compared to RVP's ROE of -0.08%. Regarding short-term risk, SOLV is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
SOLV vs RGNT Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, RGNT has a market cap of 13.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while RGNT trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas RGNT's P/E ratio is -0.08. In terms of profitability, SOLV's ROE is +0.29%, compared to RGNT's ROE of N/A. Regarding short-term risk, SOLV is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
SOLV vs FEMY Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, FEMY has a market cap of 6.9M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while FEMY trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas FEMY's P/E ratio is -6.33. In terms of profitability, SOLV's ROE is +0.29%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, SOLV is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
SOLV vs NSTG Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas NSTG's P/E ratio is -0.03. In terms of profitability, SOLV's ROE is +0.29%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, SOLV is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
SOLV vs NXGL Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, NXGL has a market cap of 4.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while NXGL trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas NXGL's P/E ratio is -1.45. In terms of profitability, SOLV's ROE is +0.29%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, SOLV is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NXGL's competition here
Lucyd, Inc (NASDAQ: LUCY)
SOLV vs LUCY Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, LUCY has a market cap of 4.6M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while LUCY trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas LUCY's P/E ratio is -0.43. In terms of profitability, SOLV's ROE is +0.29%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, SOLV is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
SOLV vs POAI Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas POAI's P/E ratio is -0.03. In terms of profitability, SOLV's ROE is +0.29%, compared to POAI's ROE of -107.05%. Regarding short-term risk, SOLV is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check POAI's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
SOLV vs GCTK Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, GCTK has a market cap of 2.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while GCTK trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas GCTK's P/E ratio is -0.02. In terms of profitability, SOLV's ROE is +0.29%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, SOLV is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
SOLV vs MHUA Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas MHUA's P/E ratio is 0.25. In terms of profitability, SOLV's ROE is +0.29%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, SOLV is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
SOLV vs GMVD Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas GMVD's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.29%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, SOLV is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
SOLV vs GMVDW Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas GMVDW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.29%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, SOLV is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
SOLV vs AVGR Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas AVGR's P/E ratio is -0.05. In terms of profitability, SOLV's ROE is +0.29%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, SOLV is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
SOLV vs NXGLW Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas NXGLW's P/E ratio is -0.04. In terms of profitability, SOLV's ROE is +0.29%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, SOLV is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
SOLV vs LUCYW Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas LUCYW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.29%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, SOLV is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
SOLV vs APR Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, APR has a market cap of 0. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas APR's P/E ratio is 22.59. In terms of profitability, SOLV's ROE is +0.29%, compared to APR's ROE of +9.81%. Regarding short-term risk, SOLV is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
SOLV vs HRC Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, HRC has a market cap of 0. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas HRC's P/E ratio is 41.92. In terms of profitability, SOLV's ROE is +0.29%, compared to HRC's ROE of +0.14%. Regarding short-term risk, SOLV is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
SOLV vs IIN Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, IIN has a market cap of 0. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas IIN's P/E ratio is 226.45. In terms of profitability, SOLV's ROE is +0.29%, compared to IIN's ROE of -0.00%. Regarding short-term risk, SOLV is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
SOLV vs ALOG Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ALOG's P/E ratio is 40.93. In terms of profitability, SOLV's ROE is +0.29%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
SOLV vs IVTY Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas IVTY's P/E ratio is -3.80. In terms of profitability, SOLV's ROE is +0.29%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, SOLV is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
SOLV vs ATRS Comparison August 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 15.3B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, SOLV is priced at $88.59 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.48, whereas ATRS's P/E ratio is 14.95. In terms of profitability, SOLV's ROE is +0.29%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, SOLV is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ATRS's competition here